Senseonics (SENS)
Develops implantable Eversense systems for long-term glucose monitoring in adults with diabetes.
Something off on this page? Send us feedback.
Develops and manufactures Eversense 365, an FDA-cleared implantable continuous glucose-monitoring system for adults with diabetes. U.S. sales, marketing, and distribution returned in-house in January 2026, while Ascensia retains non-exclusive rights in specified European territories.
Develops and manufactures the Eversense 365 continuous glucose-monitoring system, an implantable product cleared by the FDA for use in adults with diabetes. The technology evolved from earlier Eversense sensors with shorter approved wear periods.
Senseonics took direct responsibility for U.S. sales, marketing, and distribution in January 2026, supported by its own sales force. Ascensia previously held worldwide distribution rights and now has non-exclusive rights in specified European territories.
Direct commercialization changed the U.S. operating model. The product's permitted U.S. use is defined by FDA clearances, while Ascensia's European distribution scope follows the agreement.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | D.A. Davidson | Target | Target: — | Target: $15 |
| Jul 15, 2026 | Mizuho Securities | Target | Target: — | Target: $18 |
| May 12, 2026 | H.C. Wainwright | Target | Target: $1.10 | Target: $14 |
| May 11, 2026 | Stifel Nicolaus | Target | Target: $9 | Target: $8 |
| Mar 3, 2026 | Stifel Nicolaus | Target | Target: — | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $142.7M · Total debt $61.8M · Total assets $176.8M · Shareholders' equity $90.3M
- Revenue
- $14.5M
- Operating income
- −$36.0M
- Net income
- −$36.7M
No dividends on record.
| Institutions | 50.85% | 21.25M shares | |
|---|---|---|---|
| 113 holders · as of Jun 30, 2026 | |||
| Insiders | 4.52% | 1.89M shares | |
| 11 holders · as of Aug 20, 2026 | |||
| Other | 44.63% | 18.66M shares | |
| remainder | |||
41.79M company shares as of Sep 18, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (52.87M in the company's Sep 22, 2026 report, 41.79M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sessa Capital Im, L.P.Institution | 10.62% | 4.44M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.68% | 2.79M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.26% | 1.78M | as of Jun 30, 2026 |
Avidity Partners Management LPInstitution | 3.83% | 1.60M | as of Jun 30, 2026 |
Sio Capital Management, LLCInstitution | 3.81% | 1.59M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Douglas A. Roeder | director | +13,953 | $8.98 |
| May 12, 2026 | Douglas A. Roeder | director | +22,686 | $5.56 |
| Mar 13, 2026 | Timothy T. Goodnow | director, officer: President and CEO | +17,225 | $5.79 |
| Mar 13, 2026 | Douglas A. Roeder | director | +17,500 | $5.73 |
| Nov 10, 2025 | Edelman Steven | director | +10,000 | $6.55 |
- Dexcom
CGM portfolio with Dexcom G6, G7 and insulin-pump interoperability
- Abbott
FreeStyle Libre CGM systems with factory calibration
- MiniMed Group
Diabetes platform spanning CGM, insulin pumps and digital tools
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Senseonics | $9.89 | +1.14% | $408.7M | — | — | 8.4 | +118.1% |
| Dexcom | $90.20 | +1.16% | $33.65B | 35.2 | 32.2 | 6.8 | +13.1% |
| Abbott | $104.26 | +1.24% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| MiniMed Group | $21.13 | +0.05% | $5.93B | — | 36.7 | 1.8 | — |
| Median | 34.2 | 32.2 | 3.8 | +13.1% |